Valuation: Black Diamond Therapeutics, Inc.

Market Cap 75.28M 68.57M 63.18M 57.47M 108M 6.97B 113M 769M 306M 3.81B 282M 277M 11.95B P/E 2026 *
-1.87x
P/E 2027 * -1.4x
Enterprise Value 75.28M 68.57M 63.18M 57.47M 108M 6.97B 113M 769M 306M 3.81B 282M 277M 11.95B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
99.34%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Black Diamond Therapeutics, Inc.

1 day-5.76%
1 week-10.88%
Current month-26.40%
1 month-37.02%
3 months-40.72%
6 months-63.10%
Current year-46.09%
1 week 1.31
Extreme 1.31
1.53
1 month 1.31
Extreme 1.31
2.05
Current year 1.31
Extreme 1.31
3.97
1 year 1.31
Extreme 1.31
3.97
3 years 1.2
Extreme 1.195
7.66
5 years 1.18
Extreme 1.18
7.66
10 years 1.18
Extreme 1.18
46.25
Manager TitleAgeSince
Chief Executive Officer 62 16/09/2023
Chief Tech/Sci/R&D Officer 51 11/08/2021
Director of Finance/CFO 41 07/10/2024
Director TitleAgeSince
Director/Board Member 61 01/03/2017
Director/Board Member 47 01/12/2019
Director/Board Member 49 01/12/2018
Date Insider Type Main position Quantity % Market Cap. Importance
18/9/26 Free

Director

7,707 0.0134%
18/9/26 Free

Director

6,801 0.0118%
18/9/26
NEA Management Co. LLC
OtherCompany 0 0.0000% -
Change 5-day change 1-year change 3-year change Capi.($)
-5.76%-10.88%-65.53%-41.26% 75.28M
-2.49%-3.76%+53.38%+62.10% 63.66B
-0.63%-2.91%+6.55%+89.34% 58.56B
-2.37%-2.22%+21.77%+84.58% 54.19B
-2.19%-6.15%+12.43%+111.40% 44.66B
-1.89%-7.28%+9.30%+18.50% 40.51B
-0.93%-0.47%+19.34%+41.83% 36.27B
+1.11%-6.44%+127.46%+675.37% 34.89B
-0.80%+0.61%+76.27%+61.80% 32.26B
-2.17%+16.65%-28.89%+479.93% 31.01B
Average -1.81%-2.18%+23.21%+158.36% 40B
Weighted average by Cap. -1.48%-1.85%+31.81%+155.13%

Financials

2026 *2027 *
Net sales - -
Net income -41.16M -37.48M -34.54M -31.42M -58.94M -3.81B -61.95M -420M -167M -2.08B -154M -151M -6.53B -64.23M -58.5M -53.9M -49.03M -91.98M -5.95B -96.67M -656M -261M -3.25B -241M -236M -10.19B
Net Debt - -
Projected Income Statement - Annual - Black Diamond Therapeutics, Inc.
Logo Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. Its BDTX-4933 pipeline product is out-licensed to Servier. BDTX-4933 is designed to target RAS and RAF alterations in solid tumors. It is exploring partnership opportunities for its FGFR2/3 selective development candidate BDTX-4876.
Employees
21
Date Price Change Volume
20/11/26 USD 1.310 -5.76% 673,414
19/11/26 USD 1.390 -2.80% 460,286
18/11/26 USD 1.430 -0.69% 603,034
17/11/26 USD 1.440 -5.88% 660,324
16/11/26 USD 1.530 +4.08% 713,905
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Black Diamond Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1.310USD
Average target price
11.00USD
Spread / Average Target
+739.69%
  1. Stock Market
  2. Stocks
  3. BDTX Stock